Advertisement

Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin’s Lymphoma

  • A. D. Ho
  • F. Del Valle
  • R. Haas
  • M. Engelhard
  • W. Hiddemann
  • H. Rückle
  • G. Schlimok
  • E. Thiel
  • R. Andreesen
  • W. Fiedler
  • W. Hunstein
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

The activity of mitoxantrone in patients with pretreated aggressive non-Hodgkin’s lymphoma (NHL) has been demonstrated in several phase II studies [1–3]. In a previous phase II trial, the present authors investigated the efficacy of mitoxantrone combined with cytarabine (Ara-C) in conventional doses for patients with refractory disease [4], but the response rates did not seem to have improved as compared with mitoxantrone alone. Encouraging results have been reported on the use of high-dose Ara-C alone in relapsed NHL [5–7]. In patients with refractory acute leukemia, the combination of high-dose Ara-C and mitoxantrone has been shown to be active [8, 9]. We have initiated a series of studies with this combination for refractory NHL.

Keywords

Clin Oncol Autologous Stem Cell Transplantation High Dose Cytosine Arabinoside Refractory Acute Leukemia Diffuse Histiocytic Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Coltmann CA Jr, McDaniel TM, Balcerzak SP et al. (1982) Mitoxantrone hydrochloride in lymphoma. Cancer Treat Rev 10: 73–76CrossRefGoogle Scholar
  2. 2.
    Gams RA, Steinberg J, Posner L (1984) Mitoxantrone in malignant lymphoma. Sem-in Oncol 1 [Suppl] 47–49Google Scholar
  3. 3.
    Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105: 67–81PubMedGoogle Scholar
  4. 4.
    Ho AD, Dörken B, Hunstein W (1985) Mitoxantrone Monotherapie and in Kombination mit Cytosin-Arabinosid bei refraktären Hodgkin and Non-Hodgkin-Lymphomen. Cancer Res Clin Oncol 111: 105CrossRefGoogle Scholar
  5. 5.
    Kantarjian H, Barlogie B, Plunkett Wet al. (1983) High dose cytosine arabinoside in non-Hodgkin’s lymphoma. J Clin Oncol 1: 689–694PubMedGoogle Scholar
  6. 6.
    Shipp MA, Takvorian RC, Canellos GP (1984) High-dose cytosine arabinoside: active agent in treatment of non-Hodgkin’s lymphoma. Am J Med 77: 845–850PubMedCrossRefGoogle Scholar
  7. 7.
    Adelstein DJ, Lazarus HM, Hines JD et al. (1985) High-dose cytosine arabinoside in previously treated patients with poor prognosis non-Hodgkin’s lymphoma. Cancer 56: 1493–1496PubMedCrossRefGoogle Scholar
  8. 8.
    Hiddemann W, Kreutzmann H, Straif K. Ludwig WD, Mertelsmann R, DonjuijsenAnt R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine-arabinoside and mitoxantrone. A highly effective regimen in refractory adult acute myeloid leukemia. Blood 69: 744–749PubMedGoogle Scholar
  9. 9.
    Hiddemann W, Büchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzenburg S, Donjuijsen-Ant R, Lengfelder E, Hoelzer D (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone ( HAM ). Leukemia 4: 637–640PubMedGoogle Scholar
  10. 10.
    Ho AD, Del Valle F, Ruckle H, Schwammborn J, Schlimok G, Hiddemann W, Meusers P, Dörken B, Hunstein W (1989) Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin’s lymphoma. Cancer 664: 1388–1392CrossRefGoogle Scholar
  11. 11.
    The non-Hodgkin’s Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 49: 2112–2123CrossRefGoogle Scholar
  12. 12.
    Armitage JO, Dick FR, Corder MP et al. (1982) Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine, and prednisone ( CHOP ). Cancer 50: 1695–1702PubMedCrossRefGoogle Scholar
  13. 13.
    Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: An effective regimen of patients with lymphoma who have relapses after initial combination chemotherapy. Blood 60: 693–697PubMedGoogle Scholar
  14. 14.
    Laurence J, Coleman M, Allen SL, Silver RT, Pasmantier M (1982) Combination chemotherapy of advanced diffuse histiocytic lymphoma with six-drug COP-BLAM regimen. Ann Intern Med 97: 190–195PubMedGoogle Scholar
  15. 15.
    Thiel E, Gerhartz HH, Brittinger G (1988) Response-adapted COP-BLAM/IMVP-16 chemotherapy for advanced stage aggressive non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 7: 244Google Scholar
  16. 16.
    Fisher RI, De Vita VT Jr., Hubbard SM et al. (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304–309PubMedGoogle Scholar
  17. 17.
    Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102: 596–602PubMedGoogle Scholar
  18. 18.
    Skarin AT, Canellos GP, Rosenthal DS et al. (1983) Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents ( M-BACOD ). J Clin Oncol 1: 91–97PubMedGoogle Scholar
  19. 19.
    Ho AD, Del Valle F, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Haas R, Thiel E, Andrcesen R, Fiedler W, Frisch J, Schulz G, Hunstein W (1990) Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin’s lymphoma. Cancer 66: 423–430PubMedCrossRefGoogle Scholar
  20. 20.
    Miller AB, Hoogstraten B, Staquet M et al. (1981) Reporting results of cancer treatment. Cancer 47: 207–214PubMedCrossRefGoogle Scholar
  21. 21.
    Heinz R, Dittrich CH, Ludwig H et al. (1986) Results of a new combination chemotherapy (etoposide-ifosphamide-mitoxantrone) in advanced NHL. Cancer Res Clin Oncol 111: [Suppl] 38CrossRefGoogle Scholar
  22. 22.
    Landys KE (1988) Mitoxantrone in combination with sterecyte (NOSTE) in treatment of unfavorable non-Hodgkin’s lymphoma. Invest New Drugs 6: 105–113PubMedCrossRefGoogle Scholar
  23. 23.
    Coiffier B, Gisselbrecht C, Vose J, Tilly H, Herbrecht R, Bosly A, Armitage JO (1991) Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 9: 211–219PubMedGoogle Scholar
  24. 24.
    Hoskins PJ, Ng V, Spinelli J, Klimo P, Connors JM (1991) Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 9: 220–226PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. D. Ho
    • 1
    • 2
  • F. Del Valle
    • 3
  • R. Haas
    • 1
  • M. Engelhard
    • 4
  • W. Hiddemann
    • 5
  • H. Rückle
    • 6
  • G. Schlimok
    • 7
  • E. Thiel
    • 8
  • R. Andreesen
    • 9
  • W. Fiedler
    • 10
  • W. Hunstein
    • 1
  1. 1.Department of Internal MedicineUniversity of HeidelbergHeidelbergGermany
  2. 2.Northeastern Ontario Regional Cancer CentreSudburyCanada
  3. 3.Städtische Kliniken OldenburgOldenburgGermany
  4. 4.Department of Internal MedicineUniversity of EssenEssenGermany
  5. 5.Department of Internal MedicineUniversity of MünsterMünsterGermany
  6. 6.Department of Internal MedicineUniversity of WürzburgWürzburgGermany
  7. 7.Zentralklinikum AugsburgAugsburgGermany
  8. 8.Department of Internal Medicine, Klinikum SteglitzUniversity of BerlinBerlinGermany
  9. 9.Department of Internal MedicineUniversity of FreiburgFreiburgGermany
  10. 10.Department of Oncology and HematologyUniversity of HamburgHamburgGermany

Personalised recommendations